An Exploratory, Open-label, Multicentre Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether a repeat dose administration of ATIR101 is
safe and effective when infused in patients with a hematologic malignancy following a T-cell
depleted stem cell graft from a related haploidentical donor. All patients are planned to
receive two ATIR101 doses of 2×10E6 viable T-cells/kg, unless the second dose is reduced or
halted for safety reasons.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society